Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background : Funding for product development for neglected diseases fell from 2009-2015, other than a short-term injection of Ebola funding. One impediment to mobilizing resources is a lack of information on product candidates, the estimated costs to move them through the pipeline, and the likelihood of specific launches. This study aimed to help fill these information gaps. Methods : We conducted a pipeline portfolio review to identify current candidates for 35 neglected diseases. Using an adapted version of the Portfolio to Impact (P2I) financial modelling tool, we estimated the costs to move these candidates through the pipeline over the next decade and the likely launches. Since the current pipeline is unlikely to yield several critical products, we estimated the costs to develop a set of priority “missing” products. Results: We found 685 product candidates for neglected diseases as of August 31, 2017; 538 candidates met inclusion criteria for input into the model. It would cost about $16.3 billion (range $13.4-19.8B) to move these candidates through the pipeline, with three-quarters of the costs incurred in the first 5 years, resulting in about 128 (89-160) expected product launches. Based on the current pipeline, there would be very few launches of complex new chemical entities; launches of highly efficacious vaccines for HIV, tuberculosis, or malaria would be unlikely. Estimated additional costs to launch one of each of 18 key missing products range from $13.6B-$21.8B, depending on product complexity. Over the next 5 years, total estimated costs to move current candidates through the pipeline and develop these 18 missing products would be around $4.5-5.8B/year. Conclusions : Since current annual global spending on product development is about $3B, this study suggests the annual funding gap over the next 5 years is at least $1.5-2.8B, which is probably an underestimate. The current portfolio is not balanced across health needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 2×
“The authors, when commenting the estimate of the R&D cost of a new drug published by DiMasi et al (2016), argue that “[…] the estimate can be criticized for, among other things, including $1.2B in “time costs” (the expected returns that private investors forgo while a drug is in development).””
Global health 2035: a world converging within a generation
Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A., Bustreo, F., Evans, D., Feachem, R. G. A., Frenk, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62105-4 · Cited by 1,220
Self-citationWhy has under-5 mortality decreased at such different rates in different countries?
Jamison, D. T., Murphy, S. M., & Sandbu, M. E. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.03.002 · Cited by 72 · cited 1×
“For example, Jamison and colleagues recently showed that the diffusion of such technologies accounted for about 80% of the decline in child mortality from 1970 to 2000 4 .”
Cited by
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Reid, M. J. A., Arinaminpathy, N., Bloom, A., Bloom, B. R., Boehme, C., Chaisson, R., Chin, D. P., Churchyard, G., Cox, H., Ditiu, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30024-8 · Cited by 361
Self-citationAlma Ata at 40 years: reflections from the Lancet Commission on Investing in Health
Watkins, D. A., Yamey, G., Schäferhoff, M., Adeyi, O., Alleyne, G., Alwan, A., Berkley, S., Feachem, R., Frenk, J., Ghosh, G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32389-4 · Cited by 105
Self-citationFinancing global common goods for health: when the world is a country
Yamey, G., Jamison, D., Hanssen, O., & Soucat, A. (2019) · Health Systems & Reform · doi:10.1080/23288604.2019.1663118 · Cited by 59
Self-citationSchäferhoff, M., Chodavadia, P., Martinez, S., McDade, K. K., Fewer, S., Silva, S., Jamison, D., & Yamey, G. (2019) · Health Systems & Reform · doi:10.1080/23288604.2019.1663646 · Cited by 32
Self-citationSchäferhoff, M., Zimmerman, A., Diab, M. M., Mao, W., Chowdhary, V., Gill, D., Karanja, R., Madikizela, M., Ogbuoji, O., & Yamey, G. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00206-6 · Cited by 11
Self-citation
Metadata
- Authors
- Young, R., Bekele, T., Gunn, A., Chapman, N., Chowdhary, V., Corrigan, K., Dahora, L., Martinez, S., Permar, S., Persson, J., Rodriguez, B., Schäferhoff, M., Schulman, K., Singh, T., Terry, R. F., & Yamey, G.
- Venue
- Gates Open Research
- Publisher
- F1000 Research Ltd
- Published
- 2018-04-26
- Volume
- 2
- Pages
- 23
- ISSN
- 2572-4754 (ISSN-L)
- OpenAlex
- W4246921789
- Cited by
- 26
- References
- 3
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. https://app.cochat.ai/papers/10.12688/gatesopenres.12817.1
- The paper
- Young, R., Bekele, T., Gunn, A., Chapman, N., Chowdhary, V., Corrigan, K., Dahora, L., Martinez, S., Permar, S., Persson, J., Rodriguez, B., Schäferhoff, M., Schulman, K., Singh, T., Terry, R. F., & Yamey, G. (2018). Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research. https://doi.org/10.12688/gatesopenres.12817.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.